Arbutus Biopharma/$ABUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arbutus Biopharma
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Ticker
$ABUS
Sector
Primary listing
Employees
44
Headquarters
Website
ABUS Metrics
BasicAdvanced
$836M
-
-$0.29
1.01
-
Price and volume
Market cap
$836M
Beta
1.01
52-week high
$5.10
52-week low
$2.71
Average daily volume
973K
Financial strength
Current ratio
20.533
Quick ratio
19.756
Long term debt to equity
5.405
Total debt to equity
6.025
Interest coverage (TTM)
-384.81%
Profitability
EBITDA (TTM)
-43.243
Gross margin (TTM)
-242.54%
Net profit margin (TTM)
-351.92%
Operating margin (TTM)
-287.06%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-21.01%
Return on equity (TTM)
-52.82%
Valuation
Price to revenue (TTM)
53.809
Price to book
10.07
Price to tangible book (TTM)
10.07
Price to free cash flow (TTM)
-13.762
Free cash flow yield (TTM)
-7.27%
Free cash flow per share (TTM)
-0.317
Growth
Revenue change (TTM)
53.23%
Earnings per share change (TTM)
-34.64%
3-year revenue growth (CAGR)
-22.69%
10-year revenue growth (CAGR)
-0.88%
3-year earnings per share growth (CAGR)
-20.23%
10-year earnings per share growth (CAGR)
-13.86%
Bulls say / Bears say
Combination therapy with imdusiran has functionally cured eight cHBV patients to date, including two who achieved cure without interferon, demonstrating strong antiviral activity in early-stage trials.
AB-101, the oral PD-L1 inhibitor, achieved 100% receptor occupancy at the 40 mg dose in 11 of 13 healthy volunteers without serious adverse events, showing robust target engagement and a favorable safety profile.
Arbutus has reacquired global rights to imdusiran in Greater China, ending its partnership with Qilu Pharmaceutical and regaining full control over commercial and clinical development of its lead asset.
Arbutus’ cash and marketable securities totaled $113 million at Q1 2025, which may be insufficient to fully fund its planned Phase 2b trial and continued development programs, raising the risk of future dilution.
Qilu Pharmaceutical’s decision to terminate its Greater China partnership for imdusiran indicates a reprioritization by the external partner and may highlight doubts regarding the compound’s market potential in that region.
AB-101 is still in Phase 1a/1b trials and no efficacy data in patients have been reported, maintaining clinical uncertainty and delaying key value milestones.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arbutus Biopharma stock?
Arbutus Biopharma (ABUS) has a market cap of $836M as of October 25, 2025.
What is the P/E ratio for Arbutus Biopharma stock?
The price to earnings (P/E) ratio for Arbutus Biopharma (ABUS) stock is 0 as of October 25, 2025.
Does Arbutus Biopharma stock pay dividends?
No, Arbutus Biopharma (ABUS) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Arbutus Biopharma dividend payment date?
Arbutus Biopharma (ABUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arbutus Biopharma?
Arbutus Biopharma (ABUS) has a beta rating of 1.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.